EXPAREL

Peak

bupivacaine

NDAINJECTIONINJECTABLE, LIPOSOMAL
Approved
Oct 2011
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
19

Mechanism of Action

nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers. Clinically, the order of loss of nerve function is…

Pharmacologic Class:

Amide Local Anesthetic

Clinical Trials (5)

NCT05575999Phase 1Not Yet Recruiting

Effectiveness of Bupivacaine, Ketorolac, Ketamine, vs Bupivacaine Alone in Reducing Postoperative Pocket Pain

Started Jan 2026
200 enrolled
Pain Management
NCT06252662Phase 4Recruiting

Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies

Started Oct 2024
200 enrolled
Breast Cancer
NCT05409820N/ACompleted

Comparative Analysis of Hypobaric Versus Hyperbaric Bupivacaine for Spinal Anesthesia in Day-Case Anorectal Surgery

Started Feb 2022
NCT04394533Phase 4Recruiting

Hyperbaric Prilocaine Compared With Hyperbaric Bupivacaine in Cervical Cerclage?

Started Aug 2021
135 enrolled
Cervical Incompetence in Pregnancy as Antepartum Condition
NCT04033562Phase 4Terminated

The Analgesic Efficacy of Continuous Sub-fascial Bupivacaine Infusion and Lidocaine Patches in Post-cesarean Patients With Opiate Use Disorder: A Comparative Efficacy Analysis

Started Jan 2020

Loss of Exclusivity

LOE Date
Jul 2, 2044
223 months away
Patent Expiry
Jul 2, 2044
Exclusivity Expiry
Nov 9, 2026

Patent Records (5)

Patent #ExpiryTypeUse Code
12151024
Jan 22, 2041
Product
U-4037
11179336
Jan 22, 2041
Product
U-3250
11278494
Jan 22, 2041
Product
U-3250
11304904
Jan 22, 2041
Product
U-3346
11311486
Jan 22, 2041
Product
U-3250